4results about How to "Obvious side effects" patented technology

This invention provides a traditional Chinese medicine composition for treating renal edema, pyelonephritis with ascites, and nephritis. It consists of over 20 herbs including Atractylodes lancea, Areca catechu, Saposhnikovia divaricata, and Alisma plantago-aquatica (specific formulation details can be found in the original text). It can be prepared as pills, granules, or decoctions for oral administration. Core efficacy: 1. Promotes diuresis and reduces swelling, eliminating renal ascites; 2. Clears heat and detoxifies, anti-inflammatory and antibacterial (synergistic effect on fungal infections and cervical erosion); 3. Regulates renal function and improves abnormal uric acid metabolism. Treatment plan: Mild cases: Use five basic formulas (①-⑤) composed of Codonopsis pilosula, Poria cocos, etc., taken three times daily; Severe cases: Use a potent diuretic formula containing Akebia trifoliata and Euphorbia pekinensis (one spoonful of pills twice daily); Treatment course is approximately one month, with a follow-up examination after three months. Advantages: Cure rate reaches 90%, low recurrence rate – pure traditional Chinese medicine preparation, no significant toxic side effects; also treats complications (fungal infection, cervical lesions). This treatment plan has been clinically verified through three generations and has significant efficacy in treating renal edema, ascites, and nephritis.

The present application relates to the fields of microbial technology and tumor biological therapy, and particularly relates to a bacillus pumilus and application thereof, a protein preparation and a microbial preparation. The bacillus pumilus is named bacillus pumilus BP01, is isolated from the oral cavity of healthy people, and is preserved in China Center for Type Culture Collection on April 2, 2026, with a preservation number of CCTCC NO: M2026574. The 16S rRNA gene sequence of the bacillus pumilus is SEQ ID NO: 1. Compared with the prior art, the bacillus pumilus of the present application is derived from the normal oral cavity of people and has high safety. The culture product of the bacillus pumilus can significantly inhibit the proliferation and clonogenic ability of hepatocarcinoma, hepatoblastoma, colorectal cancer, bladder cancer and endometrial cancer cells. In an in vivo animal model, the bacillus pumilus shows stable anti-tumor effect and does not cause obvious toxic side effects. The bacillus pumilus can be used as a live bacterial preparation, and can also play an anti-tumor role through culture supernatant or metabolic products, and has flexible application forms. The bacillus pumilus has good clinical transformation and industrial application prospects.

The present application relates to the use of a cyclic heptapeptide in the preparation of a medicament for reducing body weight. Specifically, the present application discloses a new use of a cyclic heptapeptide Cyclo-[TYVPKAF] or a pharmaceutically acceptable salt thereof in the preparation of a medicament for reducing body weight, preventing or treating a body weight related disease. The body weight related disease includes obesity, overweight, metabolic syndrome, type 2 diabetes, fatty liver, cardiovascular disease or osteoarthritis, etc. The present application first discovers that the specific cyclic heptapeptide has clear and convenient body weight control activity, and in particular, its orally effective characteristics provide a new choice for long-term body weight management.